A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphomaEva Hoster, Michael Unterhalt, Martin Dreyling et al.|Blood|2007Cited by 971
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registryAlessandro Pastore, Oliver Weigert, Vindi Jurinović et al.|The Lancet Oncology|2015Cited by 613
Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)Georg Lenz, Wolfgang Hiddemann, E. Heidemann et al.|Journal of Clinical Oncology|2005Cited by 573
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma NetworkOlivier Hermine, Martin Dreyling, Eva Hoster et al.|The Lancet|2016Cited by 401
Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup studyChristiane Pott, Martin Dreyling, Eva Hoster et al.|Blood|2009Cited by 269